Blood Cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment Market
North America holds the largest market share in blood cancer treatment, accumulating 38.2% share during the forecast period.
Blood Cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment Market by Application, End User & Region - Forecast 2022 - 2032
Blood Cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment Market Snapshot (2022-2032)
[309 Pages Report] Global blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment demand is anticipated to be valued at US$ 5,489.3 Million in 2022, forecast to grow at a CAGR of 10.2% to be valued at US$ 12,943.6 Million from 2022 to 2032.
Growth is attributed to increasing involvement of key and prominent companies in the R&D for Blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment across the globe.
|
Data Points |
Key Statistics |
|
Growth Rate (2016-2021) |
10.8% CAGR |
|
Expected Market Value (2022) |
US$ 5,489.3 Million |
|
Anticipated Forecast Value (2032) |
US$ 12,943.6 Million |
|
Projected Growth Rate (2022-2032) |
10.2% CAGR |
Blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) is a general term used for the cancers that affect blood, bone marrow or lymphatic system. Most of these cancers start in bone marrow where blood cells (RBC, WBC and platelets) are produced from bone marrow stem cells.
In cancerous condition, differentiation of bone marrow stem cells is interrupted to produce abnormal blood cells which hamper the normal functioning of the blood. There are 4 types of blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma)s such as leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and multiple myeloma.
Factors such as increasing government initiatives for cancer awareness, rising prevalence of cancer worldwide, and strong R&D initiatives from key players, along with the increasing demand for personalized medicine are expected to augment the growth of the Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment Market during the forecast period.
Strong costs attributed to certain therapeutics in the Blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment Market is one of the major factors that is expected to hamper the market growth in the certain emerging regions over the analysis period.
Let us know your requirement to get
100% FREE customization
Which Are Some Prominent Drivers Spearheading Blood Cancer (Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma) Treatment Market Growth?
High incidence rate of blood cancers in US (leukemia-13.0, NHL-19.8, HL-2.7, myeloma-6.7 cases per 100,000 population in 2014) is one of the major factors for the growth of blood cancer treatment market in the US. In addition, advancement in technology, personalized medicine, cost effective treatment procedures are few other factors that are expected to fuel the growth of global blood cancer treatment market during the forecast period.
Moreover, increasing involvement of key and prominent companies in the R&D is leading to strong pipeline candidates, which is another factor that is anticipated to boost the growth of the blood cancer treatment market over the analysis period.
Many biopharmaceutical market players like Spectrum Pharmaceuticals and Amgen, are showing increasing interest for the development of new products. This increasing interest into treatment products is due to increasing number of individuals are suffering from blood cancer.
For instance, Kura Oncology is conducting a clinical trial for a pipeline candidate called tipifarnib for the disease indication of peripheral T-cell lymphoma and currently, the clinical trial is in Phase II, and received the fast-track designation from the FDA in March 2020. This factor is anticipated to further drive the growth of the blood cancer treatment market during forecast period.
What Are The Challenges Faced By The Blood Cancer Treatment Industry?
The divergent nature of blood cancers and increasing stringency in the regulatory requirements are some of the major factors that are expected to impede the growth of the blood cancer treatment market over the analysis period.
Though the prevalence of blood cancer, there are firm factors that are restraining the adoption of these therapeutics used in treatment. The significant limiting factors restraining the growth include the lower lymphoma treatment rates in emerging countries.
This is attributed to high costs of therapies. This results in a limited number of individuals undergoing this treatment, and a large number of these patients are not able to afford treatments such as immunotherapies.
Most of the times, the cost of such products is not accessible and affordable to the poor patients. In addition, the unavailability of suitable payment plans for treatment of these diseases is another major factor that is anticipated to hinder the market growth in the forthcoming years.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhy Is North America Emerging As An Opportunistic Blood Cancer Treatment Market?
In terms of regional platform, North America holds the largest market share in Blood cancer treatment market. The region is expected to accumulate a 38.2% market share in 2022. There has been a tremendous increase in cell-based research activities over the past decade.
Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness on personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the US.
The Canadian government is taking various initiatives to support leukemia research and develop novel immunotherapies. For instance, in January 2016, the Canadian government announced the provision of USD 20 million to the Centre for Commercialization of Regenerative Medicine (CCRM) to help establish a stem cell therapy development facility in Toronto (Canada).
How Is Europe Contributing To Growth Of The Blood Cancer Treatment Market?
According to Future Market Insights, Europe is expected to hold significant growth opportunities for blood cancer treatment, and is expected to reach at a share of 28.7% in 2022. The second most dominant market is expected to be Europe in the forecast period, and the reasons for the region’s high share includes the high number of individuals requiring treatment arising from the region and also the high usage of advanced therapeutics.
Moreover, factors such as the higher prevalence of lymphoma, the greater awareness amongst the patient population for lymphoma treatment, higher rate of adoption of advanced lymphoma therapeutic drugs, and the greater healthcare expenditure of the region are also expected to escalate the growth of the blood cancer treatment market during the forecast period.
In addition, constant R&D by key market players in the form of clinical trials for new drug candidate for lymphoma treatment have also boosted the market in the region.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Where Does Asia-Pacific Region Stand In The Blood Cancer Treatment Market?
According to Future Market Insights, Asia-Pacific is expected to grow with lucrative growth opportunities for blood cancer treatment market, and is expected to reach at a significant share of 24.2% in 2022.
The key reasons for the region’s growth rate include the approvals of key drugs such as Kymriah (tisagenlecleucel) in Japan for lymphoma treatment, the under tapped market potential of the region and also the existence of a large potential patient population needing treatment, which together are estimated to drive the market growth during forecast period.
Moreover, with the increasing burden of various forms of lymphoma during forecast period, the blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment market in the region is expected to experience growth in the future due to increasing demand for lymphoma therapeutic products.
How Is Middle East & Africa Contributing To Growth Of The Blood Cancer Treatment Market?
According to Future Market Insights, Middle East & Africa is expected to provide significant growth opportunities for blood cancer treatment market, and is expected to reach at a share of 12.8% in 2022.
The strong economic growth prospects in the region is one of the major factors that is expected to propel the growth of the blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment market over the analysis period.
Furthermore, the market is expected to develop in the future due to increasing healthcare expenditure and rising demand for advanced therapeutics by the patient population for this treatment in the region.
Role Of Start-Ups In Blood Cancer Treatment Market
There are many prominent market players in the Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment market such as:
- Carer
- 4baseCare
- Dignite
- Hospido
- Onward Assist
- Mammomobile
- Oncophenomics
- Tzar Labs
- NIRAMAI
- ONCO
- OncoStem Diagnostics
- Sascan
- Adaptive Biotechnologies
- Genoptix
- CureMetrix
- Enlitic
- Entopsis
- Freenome
- Globavir Biosciences
- Notable Labs
- Oncora Medical
- Proscia
- SkinVision
- Zumutor
- Epigeneres
Players are working hand-in-hand to provide the best-in-class blood cancer treatment for enhancing the global arena. However, there are many global start-ups in the Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment Market, that are stepping forward in matching the requirements of the Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment domain.
- In May 2021, Epigeneres Biotech announced its early detection cancer test (co-developed with Tzar Labs, Singapore-a specialised molecular diagnostic company), with a pioneering breakthrough in RNA bio-markers technology– a technology that can even detect cancer in stage zero (i.e., before tumour formation).
- Founded in 2013, Zumutor Biologics ? is among a new breed of biotech startups from India focused on immuno-oncology treatment that boosts the immune system to fight cancer. What stands out about the company is its therapeutic focus on activating natural-killer cells, as opposed to the relatively more common approach of T-cell therapy.
Market Competition
Some of the key participants present in the global blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment market include:
- Novartis Pharmaceuticals
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Johnson & Johnson Pvt. Ltd.
- Celgen Corporation
- Amgen Inc.
- Teva pharmaceutical Industries Ltd.
- Bayer AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer AG, and Novartis AG, account for a considerable market size, several regional level players are also operating across key growth regions, particularly in North America.
Recent Development
- In June 2021, Bayer announced that the company had submitted the supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA). The company had also submitted the application for marketing authorization application (MAA) to the European Medicines Agency (EMA) for oncology treatment combination of copanlisib and rituximab in the U.S.
- In 2021, Novartis announced strong data from the analysis of the pivotal Phase II ELARA trial of Kymriah in patients with relapsed or refractory follicular lymphoma, with one-time Kymriah infusion, which showed analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate.
- In February 2021, Bristol Myers Squibb announced that the company received an approval for cancer immunotherapy from the U.S Food and Drug Administration (FDA) for certain lymphomas. The FDA approved the therapy as a treatment for adults who have certain types of non-Hodgkin lymphoma.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 10.2% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Market Value in 2022 |
US$ 5,489.3 Million |
|
Market Value in 2032 |
US$ 12,943.6 Million |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million, and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled In The Blood Cancer (Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma) Treatment Industry Survey
Blood Cancer Treatment Market by Application:
- Blood Cancer Treatment for Biological/Immunotherapy Applications
- Blood Cancer Treatment for Chemotherapy
- Blood Cancer Treatment for Radiation Therapy
- Blood Cancer Treatment for Targeted Therapy
- Blood Cancer Treatment for Stem Cell Transplantation
Blood Cancer Treatment Market by End User:
- Blood Cancer Treatment in Hospitals
- Blood Cancer Treatment in Clinics
- Blood Cancer Treatment in Cancer Rehabilitation Centers
Blood Cancer Treatment Market by Region:
- North America Blood Cancer Treatment Market
- Latin America Blood Cancer Treatment Market
- Europe Blood Cancer Treatment Market
- East Asia Blood Cancer Treatment Market
- South Asia & Oceania Blood Cancer Treatment Market
- Middle East & Africa Blood Cancer Treatment Market
Frequently Asked Questions
What is the anticipated growth of the Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment market until 2032?
FMI projects the global Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment market to expand at a 10.2% value CAGR by 2032
Which region is forecast to be the most lucrative for Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment market growth?
North America is expected to be the most opportunistic Blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) Treatment market, expanding at a 38.2% market share
Which are some prominent blood cancer (leukemia, non-hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment providers?
Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer AG, and Novartis AG are some prominent blood cancer treatment providers
Table of Content
1. Global Market - Executive Summary 1.1. Global Market Overview 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Fact.MR Analysis and Recommendations 2. Global Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Introduction and Definition 3. Market Background and foundation Data Points 3.1. Need of the Hour for Industries 3.2. – Strategic Priorities 3.3. Life Cycle Stage 3.4. Forecast Factors: Relevance and Impact 3.5. Investment Feasibility Matrix 3.6. PESTLE Analysis 3.7. Porter’s Five Forces Analysis 3.8. Market Dynamics 3.8.1. Drivers 3.8.2. Restraints 3.8.3. Opportunity Analysis 3.8.4. Trend 4. Global Market Demand (US$ Mn) Analysis 2016-2021 and Forecast, 2022-2032 4.1. Historical Market Value (US$ Mn) Analysis, 2016-2021 4.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Application 5.1. Introduction / Key Findings 5.2. Historical Market Value (US$ Mn) Analysis By Application, 2016-2021 5.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Application, 2022-2032 5.3.1. Biological/Immunotherapy 5.3.2. Chemotherapy 5.3.3. Radiation Therapy 5.3.4. Targeted Therapy 5.3.5. Stem Cell Transplantation 5.4. Market Attractiveness Analysis By Application 6. Global Market Analysis 2016-2021 and Forecast 2022-2032, by End User 6.1. Introduction / Key Findings 6.2. Historical Market Value (US$ Mn) Analysis By End User , 2016-2021 6.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Cancer Rehabilitation Centers 6.4. Market Attractiveness Analysis By End User 7. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Region 7.1. Introduction / Key Findings 7.2. Historical Market Value (US$ Mn) Analysis By Region, 2016-2021 7.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. East Asia 7.3.5. South Asia & Oceania 7.3.6. Middle East and Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2016-2021 and Forecast 2022-2032 8.1. Introduction / Key Findings 8.2. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 8.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 8.3.1. By Country 8.3.1.1. U.S. 8.3.1.2. Canada 8.3.2. By Application 8.3.3. By End User 8.4. Market Attractiveness Analysis 8.4.1. By Country 8.4.2. By Application 8.4.3. By End User 9. Latin America Market Analysis 2016-2021 and Forecast 2022-2032 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 9.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 9.3.1. By Country 9.3.1.1. Brazil 9.3.1.2. Mexico 9.3.1.3. Rest of Latin America 9.3.2. By Application 9.3.3. By End User 9.3.4. By End Use 9.4. Market Attractiveness Analysis 9.4.1. By Country 9.4.2. By Application 9.4.3. By End User 9.4.4. By End Use 10. Europe Market Analysis 2016-2021 and Forecast 2022-2032 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 10.3.1. By Country 10.3.1.1. Germany 10.3.1.2. France 10.3.1.3. Italy 10.3.1.4. Spain 10.3.1.5. UK 10.3.1.6. BENELUX 10.3.1.7. Russia 10.3.1.8. Rest of Europe 10.3.2. By Application 10.3.3. By End User 10.3.4. By End Use 10.4. Market Attractiveness Analysis 10.4.1. By Country 10.4.2. By Application 10.4.3. By End User 10.4.4. By End Use 11. East Asia Market Analysis 2016-2021 and Forecast 2022-2032 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 11.3.1. By Country 11.3.1.1. China 11.3.1.2. Japan 11.3.1.3. South Korea 11.3.2. By Application 11.3.3. By End User 11.3.4. By End Use 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Application 11.4.3. By End User 11.4.4. By End Use 12. South Asia & Oceania Market Analysis 2016-2021 and Forecast 2022-2032 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 12.3.1. By Country 12.3.1.1. India 12.3.1.2. Thailand 12.3.1.3. Malaysia 12.3.1.4. Singapore 12.3.1.5. Vietnam 12.3.1.6. ANZ 12.3.1.7. Rest of South Asia & Oceania 12.3.2. By Application 12.3.3. By End User 12.3.4. By End Use 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Application 12.4.3. By End User 12.4.4. By End Use 13. Middle East and Africa Market Analysis 2016-2021 and Forecast 2022-2032 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 13.3.1. By Country 13.3.1.1. GCC Countries 13.3.1.2. South Africa 13.3.1.3. Israel 13.3.1.4. Rest of Middle East and Africa (MEA) 13.3.2. By Application 13.3.3. By End User 13.3.4. By End Use 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Application 13.4.3. By End User 13.4.4. By End Use 14. Market Structure Analysis 14.1. Market Analysis by Tier of Companies 14.2. Market Concentration 14.3. Market Share Analysis of Top Players 14.4. Market Presence Analysis 15. Competition Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Competition Deep Dive 15.4. Novartis Pharmaceuticals 15.4.1. Company Overview 15.4.2. Application overview 15.4.3. SWOT Analysis 15.4.4. Key Developments 15.5. Merck & Co. Inc. 15.5.1. Company Overview 15.5.2. Application overview 15.5.3. SWOT Analysis 15.5.4. Key Developments 15.6. Bristol-Myers Squibb Company 15.6.1. Company Overview 15.6.2. Application overview 15.6.3. SWOT Analysis 15.6.4. Key Developments 15.7. AbbVie Inc. 15.7.1. Company Overview 15.7.2. Application overview 15.7.3. SWOT Analysis 15.7.4. Key Developments 15.8. Johnson & Johnson Pvt. Ltd. 15.8.1. Company Overview 15.8.2. Application overview 15.8.3. SWOT Analysis 15.8.4. Key Developments 15.9. Teva Pharmaceutical Industries Ltd. 15.9.1. Company Overview 15.9.2. Application overview 15.9.3. SWOT Analysis 15.9.4. Key Developments 15.10. Bayer AG 15.10.1. Company Overview 15.10.2. Application overview 15.10.3. SWOT Analysis 15.10.4. Key Developments 15.11. Pfizer Inc. 15.11.1. Company Overview 15.11.2. Application overview 15.11.3. SWOT Analysis 15.11.4. Key Developments 15.12. Takeda Pharmaceutical Co. Ltd. 15.12.1. Company Overview 15.12.2. Application overview 15.12.3. SWOT Analysis 15.12.4. Key Developments 16. Assumptions And Acronyms Used 17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 02: Global Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 04: Global Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 05: Global Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 07: Global Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 08: Global Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032 Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2016-2021 Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2022-2032 Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2022-2032 Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2016-2021 Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2022-2032 Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2022-2032 Table 16: North America Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 17: North America Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 19: North America Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 20: North America Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 22: North America Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 23: North America Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032 Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2016-2021 Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2022-2032 Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2022-2032 Table 28: Latin America Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 29: Latin America Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 31: Latin America Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 32: Latin America Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 34: Latin America Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 35: Latin America Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032 Table 37: Europe Market Value (US$ Mn) Analysis, by Country, 2016-2021 Table 38: Europe Market Value (US$ Mn) Analysis, by Country, 2022-2032 Table 39: Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2022-2032 Table 40: Europe Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 41: Europe Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 42: Europe Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 43: Europe Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 44: Europe Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 45: Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 46: Europe Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 47: Europe Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 48: Europe Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032 Table 49: East Asia Market Value (US$ Mn) Analysis, by Country, 2016-2021 Table 50: East Asia Market Value (US$ Mn) Analysis, by Country, 2022-2032 Table 51: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2022-2032 Table 52: East Asia Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 53: East Asia Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 54: East Asia Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 55: East Asia Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 56: East Asia Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 57: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 58: East Asia Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 59: East Asia Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 60: East Asia Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032 Table 61: South Asia & Oceania Market Value (US$ Mn) Analysis, by Country, 2016-2021 Table 62: South Asia & Oceania Market Value (US$ Mn) Analysis, by Country, 2022-2032 Table 63: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Country, 2022-2032 Table 64: South Asia & Oceania Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 65: South Asia & Oceania Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 66: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 67: South Asia & Oceania Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 68: South Asia & Oceania Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 69: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 70: South Asia & Oceania Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 71: South Asia & Oceania Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 72: South Asia & Oceania Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032 Table 73: MEA Market Value (US$ Mn) Analysis, by Country, 2016-2021 Table 74: MEA Market Value (US$ Mn) Analysis, by Country, 2022-2032 Table 75: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2022-2032 Table 76: MEA Market Value (US$ Mn) Analysis, by Application, 2016-2021 Table 77: MEA Market Value (US$ Mn) Analysis, by Application, 2022-2032 Table 78: MEA Market Value (US$ Mn) Opportunity Analysis, by Application, 2022-2032 Table 79: MEA Market Value (US$ Mn) Analysis, by End User, 2016-2021 Table 80: MEA Market Value (US$ Mn) Analysis, by End User, 2022-2032 Table 81: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2022-2032 Table 82: MEA Market Value (US$ Mn) Analysis, by End Use, 2016-2021 Table 83: MEA Market Value (US$ Mn) Analysis, by End Use, 2022-2032 Table 84: MEA Market Value (US$ Mn) Opportunity Analysis, by End Use, 2022-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2016-2032 Figure 04: Global Market Incremental $ Opportunity, 2022-2032 Figure 05: Global Market Share and BPS Analysis by Application, 2022 & 2032 Figure 06: Global Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 07: Global Market Attractiveness Analysis by Application, 2022-2032 Figure 08: Global Market Share and BPS Analysis by End User, 2022 & 2032 Figure 09: Global Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 10: Global Market Attractiveness Analysis by End User, 2022-2032 Figure 11: Global Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 12: Global Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 13: Global Market Attractiveness Analysis by End Use, 2022-2032 Figure 14: Global Market Share and BPS Analysis by Region, 2022 & 2032 Figure 15: Global Market Y-o-Y Growth Projections by Region, 2022-2032 Figure 16: Global Market Attractiveness Analysis by Region, 2022-2032 Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2032 Figure 20: North America Market Incremental $ Opportunity, 2022-2032 Figure 21: North America Market Share Analysis by Country, 2022 & 2032 Figure 22: North America Market Y-o-Y Growth Projection by Country, 2022-2032 Figure 23: North America Market Attractiveness Analysis by Country, 2022-2032 Figure 24: North America Market Share and BPS Analysis by Application, 2022 & 2032 Figure 25: North America Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 26: North America Market Attractiveness Analysis by Application, 2022-2032 Figure 27: North America Market Share and BPS Analysis by End User, 2022 & 2032 Figure 28: North America Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 29: North America Market Attractiveness Analysis by End User, 2022-2032 Figure 30: North America Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 31: North America Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 32: North America Market Attractiveness Analysis by End Use, 2022-2032 Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2016-2032 Figure 36: Latin America Market Incremental $ Opportunity, 2022-2032 Figure 37: Latin America Market Share Analysis by Country, 2022 & 2032 Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2022-2032 Figure 39: Latin America Market Attractiveness Analysis by Country, 2022-2032 Figure 40: Latin America Market Share and BPS Analysis by Application, 2022 & 2032 Figure 41: Latin America Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 42: Latin America Market Attractiveness Analysis by Application, 2022-2032 Figure 43: Latin America Market Share and BPS Analysis by End User, 2022 & 2032 Figure 44: Latin America Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 45: Latin America Market Attractiveness Analysis by End User, 2022-2032 Figure 46: Latin America Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 47: Latin America Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 48: Latin America Market Attractiveness Analysis by End Use, 2022-2032 Figure 49: Europe Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 50: Europe Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 51: Europe Market Value Y-o-Y Growth and Forecast, 2016-2032 Figure 52: Europe Market Incremental $ Opportunity, 2022-2032 Figure 53: Europe Market Share Analysis by Country, 2022 & 2032 Figure 54: Europe Market Y-o-Y Growth Projection by Country, 2022-2032 Figure 55: Europe Market Attractiveness Analysis by Country, 2022-2032 Figure 56: Europe Market Share and BPS Analysis by Application, 2022 & 2032 Figure 57: Europe Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 58: Europe Market Attractiveness Analysis by Application, 2022-2032 Figure 59: Europe Market Share and BPS Analysis by End User, 2022 & 2032 Figure 60: Europe Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 61: Europe Market Attractiveness Analysis by End User, 2022-2032 Figure 62: Europe Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 63: Europe Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 64: Europe Market Attractiveness Analysis by End Use, 2022-2032 Figure 65: East Asia Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 66: East Asia Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 67: East Asia Market Value Y-o-Y Growth and Forecast, 2016-2032 Figure 68: East Asia Market Incremental $ Opportunity, 2022-2032 Figure 69: East Asia Market Share Analysis by Country, 2022 & 2032 Figure 70: East Asia Market Y-o-Y Growth Projection by Country, 2022-2032 Figure 71: East Asia Market Attractiveness Analysis by Country, 2022-2032 Figure 72: East Asia Market Share and BPS Analysis by Application, 2022 & 2032 Figure 73: East Asia Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 74: East Asia Market Attractiveness Analysis by Application, 2022-2032 Figure 75: East Asia Market Share and BPS Analysis by End User, 2022 & 2032 Figure 76: East Asia Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 77: East Asia Market Attractiveness Analysis by End User, 2022-2032 Figure 78: East Asia Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 79: East Asia Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 80: East Asia Market Attractiveness Analysis by End Use, 2022-2032 Figure 81: South Asia & Oceania Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 82: South Asia & Oceania Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 83: South Asia & Oceania Market Value Y-o-Y Growth and Forecast, 2016-2032 Figure 84: South Asia & Oceania Market Incremental $ Opportunity, 2022-2032 Figure 85: South Asia & Oceania Market Share Analysis by Country, 2022 & 2032 Figure 86: South Asia & Oceania Market Y-o-Y Growth Projection by Country, 2022-2032 Figure 87: South Asia & Oceania Market Attractiveness Analysis by Country, 2022-2032 Figure 88: South Asia & Oceania Market Share and BPS Analysis by Application, 2022 & 2032 Figure 89: South Asia & Oceania Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 90: South Asia & Oceania Market Attractiveness Analysis by Application, 2022-2032 Figure 91: South Asia & Oceania Market Share and BPS Analysis by End User, 2022 & 2032 Figure 92: South Asia & Oceania Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 93: South Asia & Oceania Market Attractiveness Analysis by End User, 2022-2032 Figure 94: South Asia & Oceania Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 95: South Asia & Oceania Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 96: South Asia & Oceania Market Attractiveness Analysis by End Use, 2022-2032 Figure 97: MEA Market Value (US$ Mn) Historical Analysis, 2016-2021 Figure 98: MEA Market Value (US$ Mn) Forecast and Analysis, 2022-2032 Figure 99: MEA Market Value Y-o-Y Growth and Forecast, 2016-2032 Figure 100: MEA Market Incremental $ Opportunity, 2022-2032 Figure 101: MEA Market Share Analysis by Country, 2022 & 2032 Figure 102: MEA Market Y-o-Y Growth Projection by Country, 2022-2032 Figure 103: MEA Market Attractiveness Analysis by Country, 2022-2032 Figure 104: MEA Market Share and BPS Analysis by Application, 2022 & 2032 Figure 105: MEA Market Y-o-Y Growth Projections by Application, 2022-2032 Figure 106: MEA Market Attractiveness Analysis by Application, 2022-2032 Figure 107: MEA Market Share and BPS Analysis by End User, 2022 & 2032 Figure 108: MEA Market Y-o-Y Growth Projections by End User, 2022-2032 Figure 109: MEA Market Attractiveness Analysis by End User, 2022-2032 Figure 110: MEA Market Share and BPS Analysis by End Use, 2022 & 2032 Figure 111: MEA Market Y-o-Y Growth Projections by End Use, 2022-2032 Figure 112: MEA Market Attractiveness Analysis by End Use, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
